Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 Partnering with Small Business to Advance Innovation in Cancer Research and... February 21, 2019 Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... June 4, 2021 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Load more HOT NEWS Working towards equal cancer care for everyone Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... Mom Fighting Breast Cancer Says Her Haunted House Is Something To... Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast...
